Nasopharyngeal carcinoma (NPC), a malignancy that develops in the upper section of the throat behind the nose, occurs in fewer than one person out of 100,000 worldwide each year. Locally advanced ...

(RTTNews) - Biopharmaceutical company Akeso Inc. (AKESF) said in a statement that its Penpulimab has been approved for the first-line treatment of recurrent or metastatic nasopharyngeal cancer or NPC, ...

DelveInsight's, “Nasopharyngeal Cancer Pipeline Insight” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Nasopharyngeal Cancer pipeline landscape. It covers the ...

Nasopharyngeal cancer refers to a relatively uncommon malignancy that begins in the nasopharynx—the upper section of the throat located behind the nose and above the back of the mouth. To understand ...

Please provide your email address to receive an email when new articles are posted on . Researchers found nearly identical 3-year PFS data among the two cohorts. Grade 3 and 4 short-term toxic effects ...

A phase I study of VB4–845 in patients with advanced, recurrent head and neck cancer on a weekly dosing scheme No significant financial relationships to disclose. This is an ASCO Meeting Abstract from ...

Researchers are continuing to study nasopharyngeal carcinoma (NPC) to understand how it develops and what it responds to. Their goal is to provide better outcomes and possible prevention. NPC is a ...

Methodology: Sixty patients with nasopharynx cancer received high dose curative radiation therapy at the authors' institute from April, 1995, to May 2001. Excluding eight patients who received high ...